Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Infant Bacterial Therapeutics AB ( ($SE:IBT.B) ) has issued an update.
Infant Bacterial Therapeutics AB has submitted the Clinical Study Report for ‘The Connection Study’ to the FDA, marking a significant step in the approval process for their drug candidate IBP-9414. With the ‘Break Through Designation’ granted, IBT anticipates a rolling review by the FDA, potentially expediting the approval process, which could significantly impact the company’s operations and market positioning in the field of live biotherapeutic products for premature infants.
More about Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (IBT) is a Stockholm-based pharmaceutical company specializing in developing and commercializing drugs for diseases affecting premature infants. The company is known for its expertise in using live bacteria as active substances, with its main focus on the drug candidate IBP-9414, a bacterial strain found in human breast milk, aimed at treating premature babies. IBT’s portfolio also includes drug candidates for treating gastroschisis, preventing retinopathy of prematurity, and eliminating vancomycin-resistant enterococci.
Average Trading Volume: 20,966
Current Market Cap: SEK796.2M
See more insights into IBT.B stock on TipRanks’ Stock Analysis page.